急性脑梗死高敏C-反应蛋白的变化及灯盏花素对其影响

目的:探讨急性脑梗死患者(ACI)血清高敏C-反应蛋白(hs-CRP)含量变化及灯盏花素对其影响。方法:65例ACI患者随机分为两组。对照组33例,给予低分子右旋糖酐500ml加胞二磷胆碱750 mg,曲克芦丁注射液0.6 g,每天静脉滴注,疗程2周;治疗组32例,在对照组的治疗基础上,加用注射用灯盏花素,5%葡萄糖500ml加入注射用灯盏花素50 mg,每天静脉滴注,疗程2周。采用胶乳增强的免疫比浊法测定治疗前后hs-CRP变化及进行中国卒中评分(CSS)。结果:急性脑梗死患者血清hs-CRP水平增高,治疗组患者治疗2周后血清hs-CRP水平明显降低(P<0.05),CSS评分改善,与对照组相比差异有统计学意义(P<0.01)。结论:灯盏花素能明显降低急性脑梗死患者血清hs-CRP水平,有利于减轻炎性反应,改善脑梗死部位缺血缺氧和缺损神经功能。

Effect of Breviscapine on high sensitivity C - reactive protein in patients with acute cerebral infarction

Objective To explore the effect of Breviscapine on changes of serum high sensitivity C -reactive protein （hs -CRP） level in the patients with acute cerebral infarction （ACI）. Method Total 65 cases of ACI were randomly divided into two groups. The conventional therapy was only used in the control group（ n = 33 ）. In the treatment group （ n = 32 ） ,50 mg Breviscapine （ diluted with 5% Glucose 500 ml） was given intravenously （once per day） for 2 weeks on the basis of conventional treatment. The levels of serum hs -CRP were measured by immunonephelometry. Results Compared with the control group, the serum level of hs - CRP in the treatment group after 2 weeks was significantly decreased （P 〈 0.05 ）, furthermore, CSS improved in the treatment group, the scores of CSS in the treatment group was more significantly striking than that in the control group （P 〈0.01 ）. Conclusion Breviscapine can decrease serum level of hs -CRP in the patients of ACI,which is useful for relief of inflammatory reaction and improvement of cerebral ischemia and hypoxia.